Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-A03211-40 | Other Identifier | ID-RCB number, ANSM | |
| AAP PREPS 2019 | Other Identifier | DGOS |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations | UNKNOWN |
| Regional Agency of Sante Nord Pas-de-Calais | OTHER |
Not provided
Not provided
Not provided
Not provided
Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption.
The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Group | Experimental |
| |
| Control Group | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clinical decision support | Other | In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team |
| Measure | Description | Time Frame |
|---|---|---|
| Number of adverse drug events such as acute renal failure and/or hyperkalemia in older hospitalized patients. | through study completion, an average of 20 days |
| Measure | Description | Time Frame |
|---|---|---|
| Presence of an adverse event related to the intervention provided ("change of prescription", "discontinuation of drug") | through study completion, an average of 20 days | |
| Therapeutic adaptations implemented in case of acute renal failure (ARF) or hyperkalemia upon hospital admission |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Bapstiste Beuscart, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Cœur-Poumon - Médecine aiguë gériatrique | Lille | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39558377 | Background | Payen A, Tlili NE, Cousein E, Ferret L, Le Bozec A, Lenglet A, Marcilly R, Pilven P, Potier A, Rousseliere C, Soula J, Robert L, Beuscart JB. Can the integration of new rules into a clinical decision support system reduce the incidence of acute kidney injury and hyperkalemia among hospitalized older adults: a protocol for a stepped-wedge, cluster-randomized trial (DETECT-IP). Trials. 2024 Nov 18;25(1):779. doi: 10.1186/s13063-024-08569-w. |
Not provided
Not provided
Not provided
Prospective, multicentre, controlled, single-blind, randomised cluster study with stepped-wedge permutations. The centres (hospitals) will be the clusters.
Not provided
Not provided
Not provided
|
| Will not receive Clinical Decision Support | Other | In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation |
|
Therapeutic changes within 72 hours of a CDSS alert for acute renal failure or hyperkalemia. Therapeutic changes include discontinuation of drug therapy, introduction of a new drug, dose reduction or change of drug
| through study completion, an average of 15 days |
| Relevance of CDSS alerts | Relevance of CDSS alerts is defined in a standard way. Each CDSS alert is evaluated by a clinical pharmacist according to their own expertise and data available in the EHR. If the alert was deemed not relevant, the clinical pharmacist did not perform any pharmaceutical intervention. The CDSS software register the classification of the alert as "not relevant". This approach was used the last 4 years in our hospital and as been published in an article published in the International Journal of Medical Informatics: Cuvelier E, Robert L, Musy E, Rousselière C, Marcilly R, Gautier S, Odou P, Beuscart JB, Décaudin B. The clinical pharmacist's role in enhancing the relevance of a clinical decision support system. Int J Med Inform. 2021 Nov;155:104568. doi: 10.1016/j.ijmedinf.2021.104568. Epub 2021 Sep 2. PMID: 34537687 | through study completion, an average of 20 days |
| Number of pharmaceutical interventions accepted | When an alert is received by the pharmacist, it is analyzed and the pharmacist forwards a pharmaceutical intervention to the physician in charge of the patient to propose a modification of the treatment (dosage, dose, stop | through study completion, an average of 20 days |
| Changes in ADEs (Adverse Drug Event) prevention/management work process induced by the introduction of alerts | Changes in the work system are identified through a comparison of its elements (tools, tasks, organization, interactions, work environment, professionals), before and after the introduction of alerts, using qualitative system engineering methods. | Through study completion, an average of 20 days |
| Cost-effectiveness of the pharmaceutical intervention | Use medico-economic data such as time spent treating an alert, cost of treating an adverse drug reaction to estimate the cost-effectiveness of the intervention | through study completion, an average of 20 days |
| ID | Term |
|---|---|
| D010342 | Patient Acceptance of Health Care |
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided